Kimberly Lerner is an Endocrinology/Metabolic physician. OpenAlex indexes 6 publications with 224 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4745 Arapahoe Ave Ste 200
Boulder, CO 803031082
Telephone
303-666-2640Provider last certified this registry record 9 Oct 2021.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Sequel Med Tech, LLCProgram year20251 payment
- Amgen Inc.Program year20251 payment
- Medtronic, Inc.Program year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
62.5%RANK Ligand Inhibitor60.9%Denosumab100%Part B, office-administered≥64 patientsBisphosphonate1.6%Zoledronic acid100%Part B, office-administered≥34 patientsMetabolism & gastrointestinal
22.8%Insulin Analog6.5%Lantus Solostar30%Humalog Kwikpen U-10016%Basaglar Kwikpen U-1008%Humalog8%Insulin Lispro6%Lantus6%Tresiba Flextouch U-1006%Novolog5%Novolog Flexpen4%Fiasp Flextouch3%Insulin Lispro Kwikpen U-1003%Insulin Aspart Flexpen2%Toujeo Solostar2%Fiasp2%Part D<11 patientsGLP-1 receptor agonist5.9%Trulicity45%Ozempic37%Mounjaro11%Rybelsus7%Part D<11 patients+ 6 more classes in this area
Hormonal (systemic)
10.5%l-Thyroxine8%Levothyroxine Sodium72%Synthroid22%Tirosint3%Levoxyl2%Unithroid1%Part D<11 patientsThyroid Hormone Synthesis Inhibitor1%Methimazole100%Part D≥28 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Journal for ImmunoTherapy of Cancer
2023 - 321 The frequency and utility of drug cessation trials in older adults with chronic eczematous dermatitis of unknown etiology
Journal of Investigative Dermatology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”